GLAXO

What GlaxoSmithKline Pharmaceuticals promised, and what happened

Every commitment management made on a call, tracked from the quarter it was made — reaffirmed, revised, diluted or quietly dropped.

Guidance record · Q1 FY27

what the last two calls moved 11 tracked 5 delivered 0 missed 6 open
  • New Product Launches (Oncology) delivered said Q3 FY25 Promised: Launch in either end of Q1 of the next year or earliest of Q1 of the next financial year or latest Q2. Q1 FY27: Oncology portfolio (Zejula and Jemperli) is part of the innovation portfolio which contributed 7-7.5% to Q1 topline, impacting 260-270 patients.
  • Total Revenue on track said Q3 FY26 Promised: Double the business to INR 8,000 crores over the next 4-5 years (12-14% annual growth). Q1 FY27: Management reaffirmed the INR 8,000 crore target over 4-5 years, requiring a 13-14% CAGR. Q1 reported growth was 15% YoY.

The rest of the ledger

Above is what the last two calls moved. Pro opens all 11 tracked commitments for GlaxoSmithKline Pharmaceuticals — every quarter's revision, the source quote behind each one, and the topics management has stopped answering.

See what Pro opens